-
GenScript ProBio Closes $220M Series C Financing for Biologics and Gene Therapy Expansion
•
Contract Development and Manufacturing Organization (CDMO) GenScript ProBio has announced the completion of a $220 million Series C financing round led by Legend Capital. Other investors include Highlight Capital, C&D Emerging Industry Investment, New Alliance Capital, Service Trade Innovation Development Guidance Fund, Huatai Zijin Investment, Gf Xinde Investment, and Ciit…
-
Roche and HKSTP Collaborate to Boost Life Sciences in Greater Bay Area
•
Swiss pharmaceutical giant Roche (SWX: ROG) has signed a multi-faceted collaboration agreement with the Hong Kong Science and Technology Parks Corporation (HKSTP) to further the development of the life sciences industry in Hong Kong and the Greater Bay Area (GBA), which includes Macau and Guangdong Province. Key Areas of CollaborationThe…
-
Burning Rock Upgrades 2022 Revenue Growth Forecast to 10% YOY
•
Guangzhou-based medical device giant Burning Rock Ltd (NASDAQ: BNR) has issued a notice upgrading its guidance on expected revenue growth for 2022. The company now projects a 10% year-on-year (YOY) increase, up from the 5% announced in November last year. This upward revision is driven by a better-than-forecast performance in…
-
Pasithea Therapeutics Partners with WuXi AppTec for API Manufacturing of PAS-004
•
US-based Pasithea Therapeutics Corp. (NASDAQ: KTTA) has announced that Chinese Contract Research Organization (CRO) WuXi AppTec (SHA: 603259) will provide active pharmaceutical ingredient (API) manufacturing support for its lead candidate PAS-004 (formerly CIP-137401). Specifically, WuXi STA, a subsidiary of WuXi AppTec, will provide Good Manufacturing Practice (GMP) manufacturing to support…
-
CDE Grants Priority Review to Takeda’s Vonicog Alfa, Zhongmei’s Rilonacept, and Zai Lab’s SUL-DUR
•
The Center for Drug Evaluation (CDE) has indicated that Takeda’s Vonicog alfa, Zhongmei Huadong Pharma’s rilonacept, and Zai Lab’s sulbactam/durlobactam (SUL-DUR) are set to obtain priority review statuses. These designations highlight the significance of these therapies in addressing critical medical needs. Vonicog Alfa: Vascular Hemophilia TreatmentVonicog alfa is a recombinant…
-
Immunofoco’s CLDN18.2-Targeted CAR-T Therapy IMC002 Accepted for CDE Review
•
China’s Center for Drug Evaluation (CDE) has accepted a clinical trial filing for IMC002, an in-house developed CLDN18.2-targeted chimeric antigen receptor (CAR)-T therapy by Suzhou Immunofoco. This marks a significant milestone for the Chinese firm, which aims to develop the drug for treating advanced digestive system tumors with CLDN18.2 expression,…
-
Keymed Biosciences’ CMG901 Shows Promising Results in Phase Ia Study for Solid Tumors
•
China-based Keymed Biosciences Inc. (HKG: 2162) has revealed the latest data update from a Phase Ia dosage escalation study assessing the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumor activity of its CMG901. The study focuses on CMG901, a Claudin 18.2 (CLDN18.2)-targeted antibody-drug conjugate (ADC) for advanced solid tumors. The data…
-
MDHC Group Raises Hundreds of Millions in Third Financing Round
•
Jiangsu-based MDHC Life Technologies (Kunshan) Co.,Ltd, a leading platform in minimally invasive surgery and life sciences consumables known as “Big Smart Manufacturing,” has reportedly raised hundreds of millions of RMB in its third financing round. The round was led by Luxin Venture Capital, with contributions from Ruicheng Private Equity Fund…
-
Staidson’s STSP-0601 Begins Phase II Study for Hemophilia Treatment
•
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced the first subject dosing in a Phase II clinical study for its Category 1 biologic STSP-0601. The study aims to evaluate the drug as an on-demand treatment for bleeding in patients with hemophilia A or B without inhibitors. This marks…
-
Everest Medicines’ EVER206 Shows Positive Phase I Results in China
•
China-based Everest Medicines (HKG: 1952) has announced top-line results from a Phase I study in China, demonstrating that EVER206 (also known as SPR206), a novel intravenous polymyxin derivative, is well-tolerated with no evidence of acute kidney injury or new safety signals. The study supports Everest’s plans to initiate next-phase clinical…
-
Bliss Bio Raises RMB 100 Million in Series B+ Financing for Oncology Pipeline
•
Hangzhou-based oncology-focused clinical-stage biotech Bliss Bio has reportedly raised over RMB 100 million (USD 14.7 million) in a Series B+ financing round. The round was led by In Capital, with contributions from Oriental Fortune Capital and Sherpa Healthcare Partners. The proceeds will be used to advance clinical studies for BB-1701,…
-
Junshi Biosciences’ Neotorch Study Achieves Superiority in Lung Cancer Trial
•
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that its randomized, double-blind, placebo-controlled, multi-center Phase III Neotorch study has completed the pre-set interim analysis. The study assessed the efficacy and safety of its programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) combined with chemotherapy as a perioperative treatment for patients…
-
Hengrui’s EZH2 Inhibitor SHR2554 Nears Breakthrough Therapy Designation
•
China-based Jiangsu Hengrui Pharmamceuticals (SHA: 600276) has announced that its enhancer for the zeste homolog 2 (EZH2) inhibitor, SHR2554, is set to obtain breakthrough therapy designation (BTD) status from the Center for Drug Evaluation (CDE) in China. The designation is for use in relapsed/refractory (r/r) peripheral T-cell lymphoma, marking a…
-
Henlius Terminates TROP2 Antibody Licensing Deal with Chiome Bioscience
•
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced the termination of a licensing deal with Japan-based Chiome Bioscience Inc. effective January 17, 2023. The agreement, originally signed in January 2021, granted Henlius exclusive development, manufacturing, and commercialization rights to Chiome’s anti-trophoblast cell surface antigen 2 (TROP2) antibody. The decision…
-
Structure Therapeutics Files for IPO on NASDAQ to Raise $119M
•
Structure Therapeutics Inc. (Nasdaq: GPCR), a Sino-US firm formerly known as ShouTi Inc., has filed for an initial public offering (IPO) on the NASDAQ stock exchange. The company aims to raise USD 119 million gross through the issuance of American Depositary Shares (ADS), though the final figure may differ. Structure…
-
Hansoh’s HS-10517 Greenlit for COVID-19 Clinical Study by NMPA
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its HS-10517, a Category 1 anti-COVID-19 drug co-developed by the Global Health Drug Discovery Institute (GHDDI). The study will focus on mild to moderate COVID-19…
-
Cowell Health Partners with Gilead Sciences to Enhance Drug Accessibility
•
Cowell Health has announced a partnership with US-based Gilead Sciences, Inc., (NASDAQ: GILD) aimed at leveraging Cowell’s smart pharmacy, integrated health management services, patient education, intelligent supply chain, and Internet “medicine + drug” platform, alongside Gilead’s expertise in disease prevention and treatment. The collaboration will focus on channel construction, operations,…
-
IASO Bio Raises RMB 500 Million in Series C1 Funding for Cell Therapy Pipeline
•
China-based IASO Biotherapeutics has announced the completion of a nearly RMB 500 million (USD 73.7 million) Series C1 funding round. The round was led by Shanghai Guoxin Investment & Development, Efung Capital, Shanghai Waigaoqiao Free Trade Zone Group, Nanjing Jiangbei New Area State-owned Asset Management, Housen Care Brothers, and Hongcheng…
-
Junshi Biosciences’ COVID-19 Drug JT001 (VV116) Accepted for NMPA Review
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its oral nucleoside analog drug JT001 (VV116) for treating COVID-19 has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step forward in the development and potential market approval of the drug in China.…
-
Bristol-Myers Squibb’s Opdivo Gains New Indication for NSCLC Neoadjuvant Therapy in China
•
US-based pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another indication approval in China for its PD-1 inhibitor Opdivo (nivolumab). The immunotherapy is now approved for use in combination with chemotherapy as neoadjuvant therapy for adult patients with resectable non-small cell lung cancer (NSCLC), regardless of PD-L1 expression levels.…
